SenzaGen (SENZA) investor relations material

Executive summary

• Achieved 10% year-over-year sales growth in Q1 2026, with revenue reaching SEK 15.0 million, driven by strong GARD® performance and complementary businesses.

• Progressed on the 2030 Growth Plan and strategic initiatives, including new institutional shareholder Eiffel Investment Group.

• Cost base maintained, gross margin at 69%, reflecting good cost control.

• Secured a SEK 17.5 million directed share issue, strengthening financial position.

• Gained 14 new customers, including a top five global fragrance and cosmetics group.

Financial highlights

• Q1 2026 revenue reached SEK 15.0M, up 10% year-over-year (14% FX-adjusted).

• GARD® revenue was SEK 11.0M, up 16% year-over-year (21% FX-adjusted).

• Gross margin at 69%, down from 75% in Q1 2025.

• EBITDA at SEK -1.7M and EBIT at SEK -2.1M, with EBIT impacted by currency effects.

• Cash and cash equivalents increased to SEK 38.1M following a SEK 17.5M share issue.

Outlook and guidance

• Short-term focus on disciplined growth and strict cost control to reach break-even.

• Continued focus on expanding direct sales to large multinationals and scaling operations through innovation.

• Cost-saving measures at VitroScreen expected to impact results from Q2 2026.

• Mid-term targets accelerated growth from strategic initiatives by 2027-2028, driving revenue and margin expansion.

• Long-term scaling phase aims for new markets and sustained high profitability.